<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022304</url>
  </required_header>
  <id_info>
    <org_study_id>EQN</org_study_id>
    <nct_id>NCT04022304</nct_id>
  </id_info>
  <brief_title>Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N</brief_title>
  <official_title>A Randomised, Double-blind, Three-period, Partially Replicated Crossover, Euglycaemic Glucose Clamp Study in Healthy Volunteers to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity of Biocon Insulin N and Humulin® N</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocon Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biocon Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre, randomised, double-blind, three-period, six-sequence, partially replicated
      design, crossover trial in healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed to demonstrate pharmacokinetic and pharmacodynamic equivalence
      of Biocon Insulin N with Humulin® N in healthy subjects.

      The treatment consists of one single dose of the test or reference product, administered
      during each of the three study periods, separated by 5-7 days between each dosing. The
      planned trial duration for each subject is about 17 to 43 days. Eligible subjects will
      undergo three euglycaemic clamp examinations (each of 24 hours duration).

      Depending on the sequence in which a particular subject is randomized, each subject will
      either undergo two clamps with administration of test product plus one clamp with
      administration of reference product, or, two clamps with administration of reference product
      plus one clamp with administration of test product, in random order.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Actual">December 27, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Partially replicated design, crossover trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary PK endpoint: area under the insulin concentration curve(AUCins).0-24h</measure>
    <time_frame>0-24hour</time_frame>
    <description>area under the insulin concentration curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary PK endpoint: maximum observed insulin concentration(Cins.max)</measure>
    <time_frame>0-24hour</time_frame>
    <description>maximum observed insulin concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD endpoint:area under the glucose infusion rate curve(AUCGIR)0-24h</measure>
    <time_frame>0-24hour</time_frame>
    <description>area under the glucose infusion rate curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD endpoint:maximum observed glucose infusion rate (GIRmax)</measure>
    <time_frame>0-24hour</time_frame>
    <description>maximum observed glucose infusion rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary PK endpoint: area under the insulin concentration-time curve(AUCins).0-infinity</measure>
    <time_frame>0-24 hours</time_frame>
    <description>area under the insulin concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK endpoint: area under the insulin concentration-time curve(AUCins).0-12h</measure>
    <time_frame>0-12hour</time_frame>
    <description>area under the insulin concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK endpoint: area under the insulin concentration-time curve(AUCins).12-24h</measure>
    <time_frame>12-24hour</time_frame>
    <description>area under the insulin concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK endpoint:time to maximum observed insulin concentration (tmax.ins)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>time to maximum observed insulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK endpoint:terminal elimination rate constant of insulin (λz)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>terminal elimination rate constant of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK endpoint: terminal elimination half-life (t½)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>terminal elimination half-life calculated as t½=ln2/λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK endpoint: time(t)50%-INS(early)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>time to half-maximum before Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK endpoint: time(t)50%-INS(late)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>time to half-maximum after Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PD endpoint: areas under the glucose infusion rate curve(AUCGIR).0-12h</measure>
    <time_frame>0-12hours</time_frame>
    <description>areas under the glucose infusion rate curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PD endpoint: areas under the glucose infusion rate curve(AUCGIR).12-24h</measure>
    <time_frame>12-24hours</time_frame>
    <description>areas under the glucose infusion rate curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PD endpoint: time to maximum glucose infusion rate(tmax.GIR)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>time to maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PD endpoint:time to half-maximum glucose infusion rate before GIRmax (tGIR.50%-early)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>time to half-maximum glucose infusion rate before GIRmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PD endpoint: time to half-maximum glucose infusion rate after GIRmax (tGIR.50%-late)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>time to half-maximum glucose infusion rate after GIRmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PD endpoint: Onset of action</measure>
    <time_frame>0-24 hours</time_frame>
    <description>time from trial product administration until blood glucose concentration has decreased at least 5 mg/dL from baseline, where baseline is defined as the mean of blood glucose levels from -6, -4, and -2 minutes before trial product administration as measured by ClampArt(name of Clamp Devise))</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoint: Number of subjects with Adverse Events (AEs), clinically significant changes in Physical examination, Vital signs. Local tolerability/ Injection site reactions</measure>
    <time_frame>First dose to followup period (Total duration: 21 days approximate)</time_frame>
    <description>Number of subjects with Adverse Events (AEs), clinically significant changes in Physical examination, Vital signs.
Local tolerability/ Injection site reactions</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoint: Number of subjects with clinically significant changes in Laboratory safety parameters, Electrocardiogram (ECG)</measure>
    <time_frame>Screening and Follow-up period (Total duration: 42 days approximate)</time_frame>
    <description>Number of subjects with clinically significant changes in Laboratory safety parameters.
Number of subjects with clinically significant changes in Electrocardiogram (ECG)</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Sequence: Humulin® N- Biocon Insulin N-Humulin® N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
The treatment periods will be separated by 5-7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence: Biocon Insulin N- Humulin® N- Humulin® N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
Period 2: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.
Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
The treatment periods will be separated by 5-7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence: Humulin® N- Humulin® N-Biocon Insulin N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.
Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
The treatment periods will be separated by 5-7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
The treatment periods will be separated by 5-7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
The treatment periods will be separated by 5-7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
The treatment periods will be separated by 5-7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biocon Insulin N</intervention_name>
    <description>Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).</description>
    <arm_group_label>Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N</arm_group_label>
    <arm_group_label>Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N</arm_group_label>
    <arm_group_label>Sequence: Biocon Insulin N- Humulin® N- Humulin® N</arm_group_label>
    <arm_group_label>Sequence: Humulin® N- Biocon Insulin N-Humulin® N</arm_group_label>
    <arm_group_label>Sequence: Humulin® N- Humulin® N-Biocon Insulin N</arm_group_label>
    <arm_group_label>Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humulin® N</intervention_name>
    <description>Humulin® N (human insulin [recombinant deoxyribonucleic acid origin] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.</description>
    <arm_group_label>Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N</arm_group_label>
    <arm_group_label>Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N</arm_group_label>
    <arm_group_label>Sequence: Biocon Insulin N- Humulin® N- Humulin® N</arm_group_label>
    <arm_group_label>Sequence: Humulin® N- Biocon Insulin N-Humulin® N</arm_group_label>
    <arm_group_label>Sequence: Humulin® N- Humulin® N-Biocon Insulin N</arm_group_label>
    <arm_group_label>Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and post-menopausal female subjects. Post-menopausal defined as 12 months
             of no menses without an alternative medical cause and confirmed by a follicle
             stimulating hormone (FSH) level in the post-menopausal range (&gt;= 25.8 IU/L).

          2. Age between 18 and 55 years, both inclusive

          3. Body mass index between 18.5 and 29.0 kg/m^2, both inclusive.

          4. Fasting plasma glucose concentration &lt;= 100 mg/dl.

          5. Considered generally healthy upon completion of medical history and screening safety
             assessments, as judged by the Investigator.

        Exclusion Criteria:

          1. Known or suspected hypersensitivity to Investigational Medicinal products (IMP(s)) or
             related products.

          2. Systolic blood pressure &lt; 95 mmHg or &gt;140 mmHg and/or diastolic blood pressure &lt; 50 mm
             Hg or &gt;90 mmHg after resting for at least 5 minutes in supine position (excluding
             white-coat hypertension; therefore, a repeat test showing results within range will be
             acceptable).

          3. Pulse rate at rest outside the range of 50-90 beats per minute.

          4. Receipt of any medicinal product in clinical development within 30 days or five times
             its half-life (whichever is longer) before randomisation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Grit Andersen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH Hellersbergstraße 9]</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant Human Insulin N (rhi N)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

